Comparative Pharmacology
Head-to-head clinical analysis: LESSINA 28 versus OVCON 35.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LESSINA 28 versus OVCON 35.
LESSINA-28 vs OVCON-35
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of a progestin (levonorgestrel) and an estrogen (ethinyl estradiol). Inhibits ovulation by suppressing gonadotropin release; increases cervical mucus viscosity to impede sperm penetration, and induces endometrial changes that reduce implantation likelihood.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibiting ovulation, and increases cervical mucus viscosity, impeding sperm penetration.
One tablet (0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol) orally once daily for 28 days, starting on the first day of menstrual cycle.
One tablet (35 mcg ethinyl estradiol and 0.4 mg norethindrone) orally once daily.
None Documented
None Documented
Terminal elimination half-life: 18-22 hours; clinically relevant for once-daily dosing.
Ethinyl estradiol: 5-18 hours (mean ~12 hours, biphasic); norethindrone: 5-14 hours (mean ~8 hours). Terminal half-life relevant for once-daily dosing.
Renal: 30% as unchanged drug and metabolites; biliary/fecal: 70% as metabolites.
Renal 60% (metabolites, glucuronide conjugates), fecal 10%, biliary 5%, remainder via other pathways.
Category C
Category C
Oral Contraceptive
Oral Contraceptive